Sam Altman's 2026 Portfolio: OpenAI at $852B, Helion at $15.5B

Sam Altman closed a $122 billion fundraising round for OpenAI in March 2026, bringing the company to an $852 billion valuation, while his fusion energy startup Helion received the world's first regulatory licences for a fusion power plant and raised $465 million at a $15.5 billion valuation. The two events sit inside a four-company portfolio spanning AI software, nuclear fusion, biometric identity, and longevity medicine, each operating on a different time horizon.

OpenAI's $25 Billion ARR and a Governance Bet on Washington

OpenAI's annualized revenue run rate reached $25 billion by February 2026, up from $21.4 billion at the close of 2025, with the company generating roughly $2 billion per month and targeting $30 billion in full-year 2026 revenue. Growth is driven primarily by ChatGPT's subscription tiers across consumer and enterprise accounts. Bloomberg reported in February 2026 that OpenAI's internal modelling projects revenue exceeding $280 billion by 2030, a figure the company has shared with investors.

The capital structure has shifted substantially in 12 months. A $40 billion round led by SoftBank Group closed in March 2025 at a $300 billion post-money valuation, per Bloomberg. A further $122 billion then closed in March 2026, lifting the valuation to $852 billion, according to OpenAI's press release. The company's CFO Sarah Friar discussed the commercial scale implications in a recent interview; our earlier coverage of her remarks covers the 800 million user milestone and the advertising pivot.

Altman's personal position at OpenAI is one of the stranger facts in technology: he holds no equity in the company he leads, a structure inherited from the original non-profit formation. That has recently intersected with US politics. In early July 2026, CNBC reported that Altman had proposed giving the US government a 5 percent stake in OpenAI, worth roughly $42.6 billion at current valuation, as part of an effort to reduce regulatory pressure around the company's for-profit conversion. The California dimension of that restructuring dispute has been one of the more contested governance questions in AI this year.

Helion Hits 150 Million Degrees and Earns the World's First Fusion Licences

Helion Energy, the Redmond, Washington fusion startup in which Altman is the principal backer, logged two milestones in the first half of 2026. In February, its Polaris prototype achieved plasma temperatures of 150 million degrees Celsius using deuterium-tritium (D-T) fuel, making it the first privately funded fusion machine to reach that temperature with that fuel pairing, according to TechCrunch and Fortune. The commercial fusion threshold is generally cited at 100 million degrees; Polaris cleared it by 50 percent.

In June 2026, Helion closed a $465 million Series G led by Thrive Capital at a $15.5 billion valuation. The same month, it became the first company globally to receive the regulatory licences required to build and operate a fusion power plant, clearing two approvals from the Washington Department of Health, per Helion's announcement. Initial earthwork on its Orion commercial reactor building had begun in spring 2026.

Helion is under a contracted obligation to supply electricity to Microsoft starting in 2028, an agreement with no precedent in the fusion industry. The 2028 date was negotiated at a time when grid-connected fusion output had never been demonstrated anywhere. The February plasma milestone suggests the physics are on track; the engineering gap between Polaris test conditions and a grid-connected Orion reactor is the variable that the Series G is intended to close.

World ID Shifts to Enterprise Fees, Retro Biosciences Enters Clinical Trials

World, the biometric identity network Altman co-founded under the original Worldcoin name, now reports 25 million registered users, approximately 12 million of whom have completed iris verification through an Orb device. In 2026, the project launched World ID 4.0, replacing its earlier token-incentive distribution model with a fee structure in which businesses pay to integrate the proof-of-human verification layer into their products. Early commercial partners include Zoom, Tinder, DocuSign, and Okta, each using World ID to distinguish human users from automated accounts at the application layer. The pivot from token incentives to enterprise fees represents a structural shift in how the network is monetised, though publicly disclosed revenue figures have not been released.

Retro Biosciences occupies the longest time horizon in the portfolio. Altman provided the company's entire founding capital, $180 million, from personal funds in 2023, according to MIT Technology Review. The company raised a $1 billion Series A in January 2025, per TechCrunch, and by May 2026 had raised further capital at a $1.8 billion valuation, per StatNews. Retro is now running its first human clinical trial: a pill designed to enhance the body's clearance of protein aggregates, with Alzheimer's disease as the initial indication. The company's stated mission is to add ten healthy years to the human lifespan through in vivo gene therapies, cell replacement, and pharmacology.

What It Means

Altman runs four ventures across four technical domains with essentially no operational overlap. OpenAI generates present-day revenue; Helion is building toward a contracted power-delivery date in 2028; World ID is converting a biometric user base into a fee-based identity infrastructure layer; and Retro Biosciences is working through a clinical timeline measured in years rather than quarters. The disaggregation means execution risk is largely isolated: a delay in Helion's reactor schedule carries no direct consequence for OpenAI's subscription revenue, and a setback in Retro's Alzheimer's trial does not affect World ID's enterprise fee pipeline. What connects the four is a consistent preference for problems that produce structural infrastructure if solved, rather than products that compete on features.

Sources

• Bloomberg: OpenAI Forecasts Revenue Will Top $280 Billion in 2030
• Bloomberg: OpenAI Finalizes $40 Billion SoftBank-Led Funding at $300 Billion Valuation
• OpenAI: Accelerating the Next Phase of AI ($122B Fundraise Announcement)
• CNBC: OpenAI Proposes 5% Stake to US Government to Address Political Blowback
• TechCrunch: Fusion Startup Helion Hits Blistering Temps as It Races Toward 2028 Deadline
• Fortune: Sam Altman's Fusion Startup Helion Energy Hits 150 Million Degree Plasma Milestone
• Helion Energy: $465 Million Series G Funding Round
• Helion Energy: Clears Key Regulatory Milestone for Fusion Power Plant
• STAT News: Retro Biosciences Raises at $1.8 Billion Valuation
• MIT Technology Review: Sam Altman Invested $180 Million into a Company Trying to Delay Death
• TechCrunch: Retro Biosciences Backed by Sam Altman Is Raising $1 Billion to Extend Human Lifespan

Editorial standards: every claim is sourced. Tips: [email protected]